These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 220051)
61. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Henle G; Henle W Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020 [TBL] [Abstract][Full Text] [Related]
62. Humoral immune response in Epstein-Barr virus infections. II. IgG subclass distribution in African patients with Burkitt's lymphoma and nasopharyngeal carcinoma. Kaschka WP; Klein G; Hilgers R; Skvaril F Clin Exp Immunol; 1984 Jan; 55(1):14-22. PubMed ID: 6319056 [TBL] [Abstract][Full Text] [Related]
63. Dynamics of Epstein--Barr virus antibody titre in nasopharyngeal carcinoma. Lynn TC; Tu SM Comp Immunol Microbiol Infect Dis; 1979; 2(2-3):201-5. PubMed ID: 228893 [No Abstract] [Full Text] [Related]
64. EBV-specific humoral antibodies in nasopharyngeal carcinoma patients in Cuba. Ruiz R; Gurtsevich V; Le Riverend E Neoplasma; 1979; 26(2):125-31. PubMed ID: 224330 [TBL] [Abstract][Full Text] [Related]
65. [Relation between the growth pattern and the quantity of plasma cells of nasopharyngeal cancer (NPC) and serum EBV antibody level]. Li JT Zhonghua Zhong Liu Za Zhi; 1985 Jan; 7(1):9-11. PubMed ID: 2983963 [No Abstract] [Full Text] [Related]
66. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597 [TBL] [Abstract][Full Text] [Related]
67. [Studies on the relationship between clinical course and antibody titer to Epstein-Barr virus in nasopharyngeal carcinoma (author's transl)]. Inuyama Y; Saito S; Ozu R; Horiuchi M; Asaoka K Nihon Jibiinkoka Gakkai Kaiho; 1975 Dec; 78(12):1237-43. PubMed ID: 176338 [No Abstract] [Full Text] [Related]
68. Epstein-Barr virus-specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma. Lanier AP; Henle W; Bender TR; Henle G; Talbot ML Int J Cancer; 1980 Aug; 26(2):133-7. PubMed ID: 6259065 [TBL] [Abstract][Full Text] [Related]
69. Complement-fixing antibody to Epstein-Barr virus soluble antigen in populations at high and low risk for nasopharyngeal carcinoma. Levine PH; Ebbesen P; Connelly RR; Das S; Middleton M; Mestre M Int J Cancer; 1982 Mar; 29(3):265-8. PubMed ID: 6279526 [TBL] [Abstract][Full Text] [Related]
70. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Joab I; Nicolas JC; Schwaab G; de-Thé G; Clausse B; Perricaudet M; Zeng Y Int J Cancer; 1991 Jul; 48(5):647-9. PubMed ID: 1649137 [TBL] [Abstract][Full Text] [Related]
71. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561 [TBL] [Abstract][Full Text] [Related]
72. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma]. Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737 [TBL] [Abstract][Full Text] [Related]
73. [A modified 131 I immuno-autoradiographic method for detection of serum EB virus VCA-IgA antibody in nasopharyngeal carcinoma]. Shang M Zhonghua Zhong Liu Za Zhi; 1982 Nov; 4(4):262-4. PubMed ID: 6299669 [No Abstract] [Full Text] [Related]
74. Epstein-Barr Virus antibodies in patients with carcinoma of the nasopharynx and carcinoma of other sites in the head and neck. Sako K; Minowada J; Marchetta FC Am J Surg; 1975 Oct; 130(4):437-9. PubMed ID: 170838 [TBL] [Abstract][Full Text] [Related]
75. Homology of Epstein-Barr virus DNA in nasopharyngeal carcinomas from Kenya, Taiwan, Singapore and Tunisia. Pagano JS; Huang CH; Klein G; de-Thé G; Shanmugaratnam K; Yang CS IARC Sci Publ (1971); 1975; (11 Pt 2):179-90. PubMed ID: 191360 [No Abstract] [Full Text] [Related]
76. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Hsu WL; Chen JY; Chien YC; Liu MY; You SL; Hsu MM; Yang CS; Chen CJ Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1218-26. PubMed ID: 19336547 [TBL] [Abstract][Full Text] [Related]
77. Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Foong YT; Cheng HM; Sam CK; Dillner J; Hinderer W; Prasad U Int J Cancer; 1990 Jun; 45(6):1061-4. PubMed ID: 1693600 [TBL] [Abstract][Full Text] [Related]
78. [Investigation of 2 families with clustering of nasopharyngeal carcinoma and detection of serum VCA-IgA antibody among their members]. Tang ZH Zhonghua Yi Xue Za Zhi; 1983 Sep; 63(9):553-5. PubMed ID: 6317146 [No Abstract] [Full Text] [Related]
79. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT; Yeh CY Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898 [TBL] [Abstract][Full Text] [Related]
80. Further studies on antibodies to early antigens induced by Epstein-Barr virus in nasopharyngeal carcinoma patients. Ida S; Hinuma Y; Chu CT; Chiou JF; Lai JG Gan; 1973 Dec; 64(6):545-53. PubMed ID: 4360581 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]